Nutrients

Probiotics for Digestive Symptoms During COVID-19: A Remote Placebo-Controlled Trial

Updated

Abstract

Of the 30 patients, 26 completed the study assessing the effects of a probiotic on gastrointestinal symptoms during COVID-19.

  • Patients reported improvements in respiratory symptoms and gastrointestinal quality of life over the study period, regardless of treatment.
  • Infected patients displayed significant changes in their fecal compared to healthy controls, including increased Bacteroidetes and decreased levels of certain bacterial families.
  • Probiotic treatment led to significant modulation of the microbiome's beta diversity and introduced a specific bacterial strain.
  • No changes were observed in symptoms, COVID-19-related bacterial taxa, or the fecal due to the probiotic intervention.

Simplified

Key numbers

26
Participants Completed Study
Out of 30 initially randomized patients
24
Healthy Controls Sampled
Healthy volunteers served as comparison
W54
Probiotic Strain Introduced
Significant modulation of beta diversity observed

Full Text

What this is

  • This study investigates the effects of a multispecies probiotic on gastrointestinal symptoms in patients with mild COVID-19 during home quarantine.
  • Thirty patients received either the probiotic Ecologic AAD or a placebo for 30 days, monitored through online surveys.
  • The study aimed to assess changes in the and symptom relief, with 24 healthy volunteers serving as controls.

Essence

  • Probiotic treatment did not significantly impact gastrointestinal symptoms or recovery time in mild COVID-19 patients, but it altered composition. Patients exhibited significant changes in their and compared to healthy controls.

Key takeaways

  • Probiotic treatment did not significantly affect gastrointestinal symptoms or recovery rates in COVID-19 patients. Both groups showed improvement over time, indicating symptom relief may occur independently of the intervention.
  • Patients with COVID-19 showed significant alterations in their fecal , including increased Bacteroidetes and decreased Christensenellaceae and Ruminococcaceae. These changes highlight the impact of COVID-19 on gut health.
  • The probiotic intervention modulated beta diversity significantly, introducing the W54 strain, but did not influence the fecal or symptomatic outcomes.

Caveats

  • The primary endpoint, stool calprotectin measurement, could not be assessed due to technical issues with the sample stabilizer. This limits the conclusions on intestinal inflammation.
  • The small sample size (26 participants completed the study) may affect the reliability of the findings and limit generalizability.
  • Remote sample collection posed challenges, including potential contamination risks and difficulties in ensuring sample integrity.

Definitions

  • microbiome: The collection of microorganisms, including bacteria, that inhabit a specific environment, such as the human gut.
  • metabolome: The complete set of metabolites present within a biological sample, reflecting metabolic activity.

Simplified

Funding

Competing interests

Angela Horvath and Vanessa Stadlbauer have received research grants, other research support, and/or speaker honoraria from the Institute Allergosan and Winclove Probiotics.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free